secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001730430-26-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M
--------------------------------------------------------------------------

- ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.
- 2026 ARCALYST revenue guidance $900-920M; gross-to-net improved to 8.4% from 9.8%.
- Cash and short-term investments $414.1M, no debt; increased $170.4M in 2025.
- KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 by year-end 2026.
- ~18% of 14,000 multiple-recurrence patients on ARCALYST; >4,150 prescribers since launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000005/0001730430-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000005/knsa-20260112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer